| Literature DB >> 35952671 |
Hajera Amatullah1, Isabella Fraschilla2, Sreehaas Digumarthi3, Julie Huang3, Fatemeh Adiliaghdam1, Gracia Bonilla4, Lai Ping Wong4, Marie-Eve Rivard5, Claudine Beauchamp5, Virginie Mercier5, Philippe Goyette5, Ruslan I Sadreyev4, Robert M Anthony6, John D Rioux5, Kate L Jeffrey7.
Abstract
How mis-regulated chromatin directly impacts human immune disorders is poorly understood. Speckled Protein 140 (SP140) is an immune-restricted PHD and bromodomain-containing epigenetic "reader," and SP140 loss-of-function mutations associate with Crohn's disease (CD), multiple sclerosis (MS), and chronic lymphocytic leukemia (CLL). However, the relevance of these mutations and mechanisms underlying SP140-driven pathogenicity remains unexplored. Using a global proteomic strategy, we identified SP140 as a repressor of topoisomerases (TOPs) that maintains heterochromatin and macrophage fate. In humans and mice, SP140 loss resulted in unleashed TOP activity, de-repression of developmentally silenced genes, and ultimately defective microbe-inducible macrophage transcriptional programs and bacterial killing that drive intestinal pathology. Pharmacological inhibition of TOP1/2 rescued these defects. Furthermore, exacerbated colitis was restored with TOP1/2 inhibitors in Sp140-/- mice, but not wild-type mice, in vivo. Collectively, we identify SP140 as a TOP repressor and reveal repurposing of TOP inhibition to reverse immune diseases driven by SP140 loss.Entities:
Keywords: Crohn’s disease; PHD; SP140; Speckled Protein; bromodomain; chromatin; epigenetic reader; inflammatory bowel disease; macrophages; topoisomerase
Mesh:
Substances:
Year: 2022 PMID: 35952671 PMCID: PMC9442451 DOI: 10.1016/j.cell.2022.06.048
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850